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Background: Poly(l-lactide) (PLLA) is a biodegradable polymer currently used in many bio-
medical applications, including the production of resorbable surgical devices, porous scaffolds 
for tissue engineering, nanoparticles and microparticles for the controlled release of drugs or 
antigens. The surfaces of lamellar PLLA single crystals (PLLA
sc
) were provided with amino 
groups by reaction with a multifunctional amine and used to adsorb an Escherichia coli-produced 
human papillomavirus (HPV)16-E7 protein to evaluate its possible use in antigen delivery for 
vaccine development.
Methods: PLLA single crystals were made to react with tetraethylenepentamine to obtain 
amino-functionalized PLLA single crystals (APLLA
sc
). Pristine and amino-functionalized 
PLLA
sc
 showed a two-dimensional microsized and one-dimensional nanosized lamellar mor-
phology, with a lateral dimension of about 15–20 µm, a thickness of about 12 nm, and a surface 
specific area of about 130 m2/g. Both particles were characterized and loaded with HPV16-E7 
before being administered to C57BL/6 mice for immunogenicity studies. The E7-specific 
humoral-mediated and cell-mediated immune response as well as tumor protective immunity 
were analyzed in mice challenged with TC-1 cancer cells.
Results: Pristine and amino-functionalized PLLA
sc
 adsorbed similar amounts of E7 protein, but 
in protein-release experiments E7-PLLA
sc
 released a higher amount of protein than E7-APLLA
sc
. 
When the complexes were dried for observation by scanning electron microscopy, both 
samples showed a compact layer, but E7-APLLA
sc
 showed greater roughness than E7-PLLA
sc
. 
Immunization experiments in mice showed that E7-APLLA
sc
 induced a stronger E7-specific 
immune response when compared with E7-PLLA
sc
. Immunoglobulin G isotyping and interferon 
gamma analysis suggested a mixed Th1/Th2 immune response in both E7-PLLA
sc
-immunized 
and E7-APLLA
sc
-immunized mice. However, only the mice receiving E7-APLLA
sc
 were fully 
protected from TC-1 tumor growth after three doses of vaccine.
Conclusion: Our results show that APLLA single crystals improve the immunogenicity of 
HPV16-E7 and indicate that E7-APLLA
sc
 could be used for development of an HPV16 thera-
peutic vaccine against HPV16-related tumors.
Keywords: poly(l-lactide), lamellar crystals, human papillomavirus, HPV16-E7, therapeutic 
vaccine
Introduction
Vaccines based on recombinant and purified antigens require adjuvants and efficient 
delivery systems to induce an optimal immune response. Particulate antigens have 
recently been proposed for vaccine development. The intrinsic adjuvant properties 
of antigens in the form of microparticles and nanoparticles have been shown in sev-
eral studies.1,2 One of the primary roles of particulate antigens in vaccination is their 
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effective uptake by antigen-presenting cells and subsequent 
delivery to lymphoid organs.1,2 Biodegradable polymers 
have also been widely investigated as vaccine adjuvants. 
They increase the bioavailability, half-life, and stability of 
the antigen while guaranteeing its safety for in vivo use and 
sustained and controlled delivery of the bound antigen.3
Polymeric systems based on particulate poly(l-lactide) 
(PLLA) or poly(lactide-co-glycolide) have been successfully 
employed to deliver antigens.4 These systems are able to acti-
vate humoral-mediated and cell-mediated immune responses 
by ensuring antigen presentation through the major histocom-
patibility complex I and II pathways. Several studies also 
show that the size and shape of particulate adjuvants affect 
the immune response.5–8 In fact, nanoparticles ranging from 
10 to 500 nm can be taken up by macrophages and dendritic 
cells to promote antigen presentation. In particular, antigens 
conjugated to 50 nm nanoparticles are preferentially taken 
up by dendritic cells.9 These kinds of immunogens, which 
stimulate both humoral-mediated and CD8 T-cell-mediated 
immune responses, were able to reduce tumor burden in two 
different animal models.8,10
Microparticulate polymers of 1–100 µm in size are useful 
for the controlled release of antigens and possibly reduce the 
number of vaccine doses required. They are currently used 
to develop monodose and needle-free mucosal vaccines. 
Microparticles deliver the antigens to microfold cells on 
mucosal surfaces after oral administration or to antigen-
presenting cells after parenteral inoculation.2
Human papillomaviruses (HPVs) are epitheliotropic 
viruses responsible for the development of genital malignant 
diseases.11 In particular, HPV16 is the main etiological agent 
of cervical cancer, being the cause of 61% of all cervical 
cancers in women worldwide.12,13 The virus is also involved 
in other anogenital and head and neck cancers.14 To prevent 
HPV infections in humans, two prophylactic HPV vac-
cines, based on recombinant virus-like particles, have been 
licensed and are currently used in humans. Both vaccines, 
Gardasil® and Cervarix®, promote capsid-specific neutraliz-
ing antibodies against oncogenic HPV16 and HPV18, while 
Gardasil also protects against HPV11 and HPV6, which 
cause benign genital condylomas.15 Therapeutic vaccines 
that can treat established HPV infections by inducing a cell-
mediated immune response have not yet been licensed for 
any genotype. Most of the therapeutic vaccines developed 
so far are based on the viral early oncoproteins E6 and E7.16 
These proteins contain several reactive T-cell epitopes and 
play a role as tumor rejection antigens in humans. Vac-
cines based on E6 and E7 can be used for both preventing 
and treating HPV-associated malignancies.17,18 Because 
of its poor immunogenic capability, due to its small size, 
E7 (11 kDa) was fused to different peptides and proteins, 
including HPV16-L1, HPV16-L2, and HPV16-E6, with the 
aim of combining prophylactic and therapeutic vaccines in 
a unique preparation. Although many developed therapeutic 
vaccines provided a good immune response in HPV16-
related tumor regression in both animal and ex vivo human 
preclinical models, only a few of them have reached the 
clinical trial phase, and there are ongoing efficacy studies 
for their approval.17,18
This investigation explores the use of pristine and sur-
face amino-functionalized lamellar poly(l-lactide) single 
crystals (PLLA
sc
 and APLLA
sc
, respectively), possessing 
a two-dimensional microsized, one-dimensional nanosized 
lamellar morphology, as a delivery system for an Escherichia 
coli-expressed HPV16-E7.19,20 The chemical and physico-
chemical properties of PLLA
sc
 and APLLA
sc
 were analyzed. 
The polymer lamellae were adsorbed with the E7 tumor 
antigen. E7-specific humoral-mediated, cell-mediated, and 
tumor-protective immune responses were evaluated in the 
HPV16 mouse tumor model, which uses the TC-1 cell line 
challenge in C57BL/6 mice.21 The results provide a novel 
delivery system for the development of an effective thera-
peutic vaccine against HPV16-associated tumors.
Materials and methods
Materials
The materials used in this study were all high purity reagents. 
PLLA (approximate molecular weight 152×103 g/mole), 
tetraethylenepentamine (TEPA), ninhydrin, dithiothreitol 
reducing agent, Tris, NaCl, NaH
2
PO
4
, Na
2
HPO
4
, sodium 
dodecyl sulfate (SDS), Tween 20, Triton X-100, Triton X-114, 
β-mercaptoethanol, bovine serum albumin, imidazole, glycerol, 
ethanol, isopropanol, acetic acid, geneticin (G418), sulfuric 
acid, and methanol were purchased from Fluka (Sigma-Aldrich 
Co., St Louis, MO, USA), Water Plus deionized water from 
Carlo Erba-Dasit (Cornaredo, Italy), and Ni-NTA resin from 
Qiagen NV (Venlo, the Netherlands). Ultrapure urea and gly-
cine were from MP Biomedicals (Santa Ana, CA, USA). The 
acrylamide-bis-acrylamide (29:1) 30% Coomassie brilliant 
blue stain and colorimetric protein assay were from Bio-Rad 
Laboratories Inc. (Hercules, CA, USA). The primary antibodies 
and horseradish peroxidase secondary antibodies were from 
Pierce (Thermo Fisher Scientific, Waltham, MA, USA). The 
tetramethyl benzidine substrate was from Vector Laborato-
ries Ltd (Peterborough, UK). The phosphate-buffered saline 
solution, fetal bovine serum, Roswell Park Memorial Institute 
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(RPMI) 1640 mammalian culture medium, and supplements 
were from Lonza Group Ltd (Basel, Switzerland). The bacterial 
culture medium and supplements were from Oxoid (Thermo 
Fisher Scientific). The mouse lymphocyte purification kit was 
from Life Technologies (Thermo Fisher Scientific, Waltham, 
MA, USA) and the interferon gamma (IFN-γ) ELISPOT kit 
was from Mabtech AB (Nacka Strand, Sweden). C57BL/6 mice 
were obtained from Charles River Laboratories (Wilmington, 
MA, USA). The aluminum specimen stubs used for scanning 
electron microscopy (SEM) were from Agar Scientific Elektron 
Technology Ltd (Stansted, UK) and the QCL-1000 Limulus 
amebocyte lysate assay was from Lonza Group Ltd.
Preparation of Pllasc and surface 
aminolysis reaction
Lamellar PLLA
sc
 were prepared as previously reported.19 
Briefly, PLLA was purified and crystallized from 0.25% 
(w/v) p-xylene solution at a T
c
 of 90°C according to the 
procedure described by Iwata and Doi.22 At the end of crystal-
lization, the single crystals were collected by centrifugation 
and repeatedly washed first with cold p-xylene and then with 
ethanol, in which they were finally suspended.
To increase the adsorption of E7 oncogenic protein and 
to control its release, free amino groups were introduced onto 
the PLLA
sc
 surface by an aminolysis reaction with distilled 
TEPA. To avoid changes in the single crystal morphol-
ogy, TEPA concentration, reaction time, and temperature 
were optimized. The PLLA
sc
 were suspended in 0.1 g/mL 
TEPA solution in isopropanol for 10 minutes at 55°C. The 
APLLA
sc
 were then repeatedly centrifuged and washed with 
isopropanol, in which they were finally suspended. The 
reaction product was characterized by Fourier transform 
infrared spectroscopy, differential scanning calorimetry, 
and water contact angle analysis. The concentration of free 
amino groups on the APLLA
sc
 surface was determined by 
ultraviolet-visible spectroscopy.
Attenuated total reflection Fourier transform infrared 
spectroscopy was performed on PLLA
sc
 and APLLA
sc
 
samples using a Nicolet 6700 instrument (Thermo Fisher 
Scientific), equipped with a Golden Gate diamond single 
reflection device (Specac Ltd, Orpington, UK). The spectra 
were acquired by co-adding 200 interferograms in the range 
of 4,000–650 cm-1 at a resolution of 2 cm-1.
The effect of the aminolysis reaction on the thermal 
properties of PLLA
sc
 was studied by differential scanning 
calorimetry carried out using DSC822e apparatus (Mettler 
Toledo, Greifensee, Switzerland) in the temperature range 
of 30°C–200°C. The temperature runs were performed on 
3–4 mg of sample under a nitrogen atmosphere at a heating 
rate of 10 K per minute.
The increase in surface hydrophilicity of PLLA due to 
the aminolysis reaction was verified by measuring the water 
wettability of pristine and amino-functionalized polymer 
films, as the single crystals are too small to be directly tested. 
The aminolysis reaction was carried out on the films under 
the same conditions used for PLLA
sc
.
Dynamic advancing (θ
a
) and receding (θ
r
) contact 
angles were measured at room temperature using a DCA-
312 dynamic contact angle analyzer. Deionized water 
(γ
w
 =72.8 mN/m) was used as a wetting medium in an immer-
sion and withdrawal cycle performed at a stage speed of 
60 µm per second.
The amount of TEPA bonded to single crystals was deter-
mined by ultraviolet-visible spectroscopy carried out using an 
HP 8452A diode array spectrophotometer (Hewlett Packard, 
Palo Alto, CA, USA) according to the procedure described by 
Cui et al using ninhydrin as an amine-specific dye.23 The con-
centration, expressed as moles per mg of APLLA
sc
 sample, 
was determined by means of a calibration curve obtained 
using known concentrations of distilled TEPA.
Expression, purification, and analysis  
of e7 protein
Histidine-tagged E7 protein was expressed and purified as 
previously described.20,24 Briefly, E. coli inclusion bodies con-
taining histidine-tagged E7 protein were lysed in a denaturing 
buffer containing 8 M urea, 10 mM NaH
2
PO
4
, 10 mM Tris-
HCl (pH 8), 300 mM NaCl, 1 mM dithiothreitol, 1% Triton 
X-114, and 1% Triton X-100 (Buffer B mode). After sonica-
tion and centrifugation at 10,000 rpm in an SS34 rotor (Sorvall 
centrifuge), the supernatant was incubated with 50% slurry 
Ni-NTA resin at room temperature for 30 minutes. To reduce 
the endotoxin content, the E7-Ni-NTA agarose suspension 
was sequentially washed in Buffer B without detergents, and 
containing 10% glycerol (100 mL), 20% ethanol (100 mL), 
and 60% isopropanol (200 mL). The isopropanol washes 
were alternated with 10 mM Tris-HCl washes (200 mL). 
The last wash was performed using 500 mL of Buffer C 
(8 M urea, 10 mM NaH
2
PO
4
, 10 mM Tris-HCl, pH 6.3). The 
protein was eluted using 500 mM imidazole in Buffer B. 
After an analytical Coomassie-stained SDS polyacrylamide 
gel electrophoresis (PAGE), the fractions containing the 
E7 protein were collected and the protein was subjected to 
two-step dialysis at 4°C in native buffer, the first contain-
ing 1 mM dithiothreitol.20 The protein was quantified by 
standard colorimetric methods (bicinchoninic acid assay). 
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Its purity and identity were monitored by 12.5% polyacryl-
amide gels in Tris-glycine buffer (SDS-PAGE) followed 
by Coomassie brilliant blue staining. The protein samples 
were denatured in SDS-loading buffer (25 mM Tris-HCl 
pH 6.8, 5% β-mercaptoethanol, 2% SDS, 50% glycerol). The 
protein identity was verified by Western blot using specific 
antibodies.25 The endotoxin contamination was as low as 
0.5 EU/mg protein, as monitored by Limulus amebocyte 
lysate assay. Transmission electron microscopy showed the 
protein assembled in particles in the 45–200 nm size range, 
as previously described.20
e7 adsorption on Pllasc and aPllasc  
and protein release experiments
Pristine PLLA
sc
 or APLLA
sc
 samples (20 mg) were incubated 
for 24 hours at room temperature with 1 mL of an E7 protein 
solution (1 mg/mL) in Tris-NaCl buffer (pH 8) under gentle 
stirring. The samples were successively centrifuged at low 
speed (300× g) and washed twice with 1 mL of Tris-NaCl 
buffer to remove unbound E7. The quantity of E7 adsorbed 
on the PLLA
sc
 and APLLA
sc
 samples was estimated by SDS-
PAGE after Coomassie brilliant blue staining of the gel and 
using known amounts of bovine serum albumin protein as a 
standard, as described in Casini et al.26 The E7-containing 
samples were designated E7-PLLA
sc
 and E7-APLLA
sc
. These 
complexes were used to immunize mice, as described in the 
Immunization and tumor protection experiments section.
For protein-release experiments, E7-PLLA
sc
 and E7- 
APLLA
sc
 suspensions (1 mL) containing about 100 µg of E7 
were washed five times with a 1 mL aliquot of phosphate-
buffered saline (pH 7.3) in Eppendorf tubes by gently 
inverting the tube three times. After each wash, the particle 
suspensions were centrifuged at low speed (300× g), the 
supernatant was removed, and the protein released was 
quantified by colorimetric (bicinchoninic acid) protein assay 
in 10 µL of supernatant.
scanning electron microscopy analysis
The morphology of PLLA
sc
, APLLA
sc
, E7-PLLA
sc
 and 
E7-APLLA
sc
 was observed by ultra-high resolution field 
emission gun scanning electron microscopy (FEG-SEM, 
FEI Company, Hillsboro, OR, USA). Secondary electron 
images were acquired with an acceleration voltage of 10 kV. 
Before analysis, the samples were gold-sputtered. For SEM 
observations of non-loaded single crystals, a drop of lamellae 
suspension in isopropanol was deposited on an aluminum 
stub and the liquid was removed through evaporation. For the 
E7-loaded samples, an aliquot of E7-PLLA
sc
 or E7-APLLA
sc
 
suspension in phosphate-buffered saline containing the same 
sample amount used for subcutaneous mouse inoculation was 
deposited on an aluminum stub, dried, and used to analyze 
the morphology of the aggregated sample.
Semiquantitative analysis of the surface of aggregated 
structures of E7-PLLA
sc
 or E7-APLLA
sc
 was carried out 
by counting surface projections (crests) from at least 50 
random fields of view for both samples at a magnification 
of 1,200×.
Immunization and tumor protection 
experiments
Female C57BL/6 mice (aged 6–8 weeks) were purchased 
from Charles River Laboratories and maintained in the ani-
mal facility at the Italian National Institute of Health under 
pathogen-free conditions for one week before the experi-
ments. Two groups of mice (n=15 per group) were inoculated 
subcutaneously in the bottom right flank with three doses of 
10 µg of E7 bound to either PLLA
sc
 or APLLA
sc
 at one-week 
intervals. Each dose contained about 33 mg of biodegradable 
polymer, corresponding to 10 µg of bound E7. The same 
dose schedule was adopted for treating one group of mice 
(n=15 per group) subcutaneously with three doses of 10 µg 
free E7.20 A fourth mouse group was inoculated with saline 
solution and used as a control (naïve). Two other groups of 
mice were inoculated only with 33 mg of pristine PLLA and 
APLLA without protein.
Two weeks after the last immunization, five mice in each 
group were euthanized to analyze the immune response, and 
ten mice were inoculated subcutaneously with 1×105 TC-1 
tumor cells per mouse. TC-1 cells are primary lung epithelial 
cells derived from C57BL/6 mice and transformed with the 
HPV16 E6, E7 and c-Ha-ras genes.21 These cells are able 
to induce a palpable tumor when inoculated in the lower 
right flank of the mouse. TC-1 cells, cultured in RPMI 1640 
supplemented with 10% fetal calf serum, 1% penicillin/
streptomycin, 2 mM glutamine, 1 mM pyruvate, and 1% 
non-essential amino acids were selected in G418 0.4 mg/mL. 
Cells at 50% confluence were harvested, counted, and rinsed 
in Hank’s medium at 1×106 cells/mL for injection into the 
mice. The challenge dose used was 1×105 cells/mouse 
(100 µL). Tumor growth was monitored by visual inspec-
tion and palpation once a week for 2 months. After this time 
interval, the mice were euthanized. The immunization and 
tumor protection experiment was performed three times.
The experiments with animals have been made minimiz-
ing any possible suffering according to the Ethical Commit-
tee of the Istituto Superiore di Sanità, Rome, Italy (protocol 
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555/SA/2012) and according to Legislative Decree 116/92 
which has implemented in Italy the European Directive 
86/609/EEC on laboratory animal protection.
antibody assay
The sera from each group of immunized mice were pooled 
and analyzed after the second and third dose of immunogens. 
To determine the anti-E7 specific immunoglobulin (Ig)G 
titer, the sera pools were serially diluted (two-fold and ten-
fold) and assayed by enzyme-linked immunosorbent assay.25 
The endpoint dilution corresponded to an optical density 
absorbance ,0.1 at 450 nm. Sera pools diluted 1:100 were 
used to analyze anti-E7 IgM, IgA and IgG isotypes (IgG1, 
IgG2b, IgG2c, and IgG3). Antigen–antibody complexes 
were detected using the following horseradish peroxidase 
secondary antibodies (Sigma-Aldrich): rabbit anti-mouse 
IgG (H + L), goat anti-mouse IgM (µ-chain specific), goat 
anti-mouse IgA (α-chain specific), and goat anti-mouse IgG1, 
IgG2b, IgG2c, and IgG3. Horseradish peroxidase activity 
was revealed using tetramethyl benzidine in the presence of 
H
2
O
2
. After 30 minutes at room temperature, the enzymatic 
reaction was stopped by adding 1 M sulfuric acid (50 µL 
per well). Washing steps were done using 400 µL per well 
of phosphate-buffered saline containing 0.05% Tween-20 in 
an automatic washer.
IFN-γ elIsPOT assay
Splenocytes from mice of the same immunization group 
were pooled and enriched in CD4+ and CD8+ cells using 
the Dynal mouse T-cell negative isolation kit. Cells were 
cultured in RPMI 1640 supplemented with 10% fetal calf 
serum, 1% penicillin/streptomycin, 2 mM glutamine, 1 mM 
pyruvate, and 1% non-essential amino acids (complete 
RPMI). The splenocyte pools (2×105 cells per well) were 
stimulated for 5 days with 5 µg/mL of two E7-CTL peptides, 
DLYCYEQL (21–28 amino acids) and RAHYNIVTF (49–57 
amino acids). The IFN-γ ELISPOT assay was performed 
using commercially available reagents. Splenocytes enriched 
with T-cells were seeded in triplicate (5×105 cells per well) in 
100 µL of complete medium with the E7 stimulator peptides. 
After 18 hours at 37°C in a humidified 5% CO
2
 incubator, 
the plates were analyzed for the presence of IFN-γ according 
to the manufacturer’s protocol. Splenocytes stimulated with 
an unrelated mixture of peptides or mitogens were used as 
the negative and positive control, respectively.27
statistical analysis
The statistical analysis was performed using the Student’s 
t-test for unpaired data. Differences were considered to be 
statistically significant at P,0.05.
Results
synthesis and characterization of Pllasc
PLLA
sc
 grown from p-xylene solution at 90°C had a lozenge 
or trunked lozenge shape with a lateral dimension of about 
20–30 µm, as observed by SEM (Figure 1A). Since it was 
not possible to determine the lamellar thickness, a value of 
about 12 nm, reported in the literature for PLLA
sc
 obtained 
under the same experimental conditions used here, was 
considered.28 Our lamellar systems were well separated with a 
smooth surface and did not show any sheaf-like aggregation. 
PLLA, like most semicrystalline polymers, can form single 
crystals with a well-defined architecture, characterized by 
an ordered inner layer sandwiched between two amorphous 
regions consisting of chain folding and cilia, ie, terminal seg-
ments. The good accessibility and reactivity of the outermost 
lamellar surface allows the introduction of suitable functional 
groups. In addition, the compact and continuous crystalline 
?????? ??????
? ?
Figure 1 scanning electron micrographs of Pllasc (A) and aPllasc (B).
Notes: a drop of Pllasc and aPllasc suspensions in isopropanol was deposited on the sample holder. The magnitude scale bars are indicated. 
Abbreviations: Pllasc, poly(l-lactide) single crystals; aPllasc, amino-functionalized poly(l-lactide) single crystals.
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core ensures the system’s morphological and mechanical 
stability. These properties are of key importance in drug 
delivery applications where the precise control of chemical or 
biochemical parameters as well as specific physicochemical 
features (particle size, surface roughness, and composition) 
are needed.
In order to evaluate the effect of surface chemistry on 
E7 protein absorption and immunogenicity, the PLLA
sc
 
surface was endowed with amino groups by an aminolysis 
reaction between PLLA
sc
 and a multifunctional amine, TEPA. 
This reaction can provide the lamella surface not just with 
amino groups but with hydroxyl functionalities as well, 
without producing any hydrolysis side reaction.29
The aminolysis reaction conditions chosen in this study 
(0.1 g/mL TEPA solution in isopropanol, 10 minutes at 
55°C), did not change the single crystal morphology or sur-
face roughness, as shown by SEM images of well dispersed 
PLLA
sc
 and APLLA
sc
 lamellae, obtained from a diluted 
isopropanol suspension (Figure 1A and B). In contrast, more 
drastic reaction conditions (such as longer reaction time, and 
a higher temperature and amine concentration) brought about 
a reduction in the lamellar lateral dimension or weakening 
of the crystal structure with lamellar fragmentation in sub-
sequent treatments (data not shown).
Because of the very high specific surface area of our sys-
tem, the aminolysis reaction may be conveniently observed 
by attenuated total reflection Fourier transform infrared 
spectroscopy. PLLA
sc
 and APLLA
sc
 sample spectra are 
shown in Figure 2A.
The APLLA
sc
 spectrum, compared with that of pristine 
lamellae showed the presence of an additional absorption 
peak centered at about 1,620 cm-1. This peak, due to amide 
C=O stretching and N-H bending, was found to be large 
because of the superimposition of various unresolved pos-
sible contributions, all resonating in the same spectral region. 
In fact, according to steric hindrance considerations, the 
formation of a primary amide involving the TEPA terminal 
NH
2
 could be favored, although the presence of a secondary 
amide cannot be excluded. Moreover, the hydrogen bond 
between the amide C=O group and TEPA protons could cause 
a red shift in the stretching absorption frequency.
The TEPA concentration on weighted amounts of APL-
LA
sc
 was determined by ultraviolet-visible spectroscopy at 
515 nm employing a ninhydrin solution. A mean concentra-
tion of (13±3) ×10-6 mol of TEPA per gram of APLLA
sc
 was 
calculated.
In order to determine the reaction yield, the following 
issues were considered: in PLLA
sc
 the polymer chain axis 
is perpendicular to the lamella basal plane; the polymer 
crystallizes in the α form, consisting of two chains with 10
3
 
helical conformation packed into an orthorhombic cell with 
a=1.07 nm, b=0.645 nm, and c=2.78 nm; and one half of the 
aminolysed chains forms an amide bond with TEPA. There-
fore, a maximum concentration of reaction sites for TEPA 
equal to 3×10-4 mol/g (equivalent to 2.3×10-6 mol/m2) can be 
inferred. This value allowed us to calculate a reaction yield of 
about 4.3%. In aminolysis reactions, reported in the literature 
and carried out on a PLLA membrane using hexamethylen-
diammine, the high hexamethylendiammine concentration 
of 1.6–2×10-3 mol/m2 was justified by polymer film rough-
ness or porosity.30 The aminolysis reaction deeply affected 
the thermal properties of PLLA
sc
 as shown in Figure 2B, 
where the differential scanning calorimetry heating profiles 
of pristine PLLA
sc
 and APLLA
sc
 are reported.
The pristine PLLA
sc
 thermogram showed an endother-
mic process at 168°C arising from the melting of original 
metastable crystals followed by a recrystallization process 
at 173°C that caused the formation of crystals with a thicker 
structure and melting at 183°C.31 As a result of the aminolysis 
reaction, the temperature of both the melting peaks decreased 
????? ????? ????? ????? ????? ??????????????????????
???
???
???
??
????
?
? ? ??????
???????
??????
???????
?? ??? ??? ??? ??? ??? ????????????????°??
???
?????
??
??
Figure 2 Attenuated total reflection Fourier transform infrared spectra of PLLAsc and aPllasc (A). Differential scanning calorimetry thermograms of Pllasc and aPllasc 
recorded at 10°c per minute (B).
Note: The arrow indicates the amide c=O stretching and N-hbending large peak (A).
Abbreviations: Pllasc, poly(l-lactide) single crystals; aPllasc, amino-functionalized poly(l-lactide) single crystals.
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and the small exothermic peak at about 173°C disappeared, 
since the shortest polymer chains involved in the reaction 
with TEPA cannot undergo the reorganization process. 
Similar thermal behavior has been already observed on 
hydrolyzed PLLA
sc
.19 Moreover, since the overall enthalpy of 
fusion of the PLLA
sc
 and APLLA
sc
 samples (ΔH
m
PLLA =72 J/g, 
ΔH
m
APLLA =70 J/g, calculated by taking into account the inte-
gral of all the endothermic and exothermic processes) did 
not significantly change, it is possible to state that the inner 
crystalline cores of the single crystals were not involved in 
the aminolysis reaction.
Since the introduction of primary and secondary amino 
and hydroxyl groups on PLLA
sc
 by the TEPA aminolysis 
reaction can increase polymer surface hydrophilicity, the 
wettability of samples was evaluated by water contact angle 
measurements. PLLA films were used in these experiments 
because the single crystals are too small to be directly 
analyzed. Film aminolysis was carried out under the same 
reaction conditions used to prepare APLLA
sc
.
The mean values of the dynamic advancing (θa) and 
receding (θ
r
) contact angles and their hysteresis (Δθ = θa - θr) 
for pristine PLLA and APLLA films are reported in Table 1. 
The data are representative of at least five independent 
experiments. Both θa and θr contact angles showed that the 
amino-functionalized sample was more hydrophilic than 
pristine PLLA. The low APLLA receding angle (θ
r
 =5°) indi-
cated nearly complete sample wettability. The high contact 
angle hysteresis found in the two samples can be ascribed to 
physicochemical surface heterogeneity. Such heterogeneity 
can be related to the presence of amorphous and crystalline 
areas as well as to the inhomogeneous distribution of the 
hydrophilic amino and hydroxyl groups in the functional-
ized sample.32,33
hPV16-e7 protein adsorption and release
APLLA
sc
 or PLLA
sc
 were incubated in an HPV16-E7 protein 
solution to generate E7-APLLA
sc
 or E7-PLLA
sc
 complexes as 
described in the Materials and methods section. The amount, 
structural integrity, and stability of the E7 protein absorbed on 
pristine PLLA
sc
 and APLLA
sc
 were analyzed by SDS-PAGE 
(data not shown).26 Despite the different chemical surface 
composition, the two E7-loaded samples bound similar 
quantities of protein. In particular, a value of 300±30 ng 
of E7 per mg of APLLA
sc
 or PLLA
sc
 was determined as 
described in Casini et al.26 Nevertheless, the protein released 
from the two substrates by controlled wash steps was different 
(Figure 3). In fact, a suitable quantity of either E7-APLLA
sc
 
or E7-PLLA
sc
 complexes was repeatedly rinsed (five times) 
with 1 mL aliquots of phosphate-buffered saline. The released 
protein in the supernatants was determined after every rinsing 
step, as described in the Materials and methods section. The 
cumulative release fraction, expressed as M(n)/M
0
, where M
0
 
is the amount of absorbed protein at the beginning and M(n) 
is the protein released at the n wash number, is reported in 
Figure 3. The results clearly show that the E7-PLLA
sc
 com-
plex (solid line) released much more protein when compared 
with E7-APLLA
sc
 (dotted line) after each wash step. In par-
ticular, E7-PLLA
sc
 lost about 80% of the protein at the end 
of the washing step; in contrast, E7-APLLA
sc
 released only 
about 25% of protein during the same treatment.
As far as the morphology of the lamellae aggregates is 
concerned, it was observed that E7-APLLA
sc
 and E7-PLLA
sc
 
showed different behavior on analysis of the SEM micro-
graphs when a drop of the particulate suspension was dried 
on an aluminum stub (Figure 4). Both E7-PLLA
sc
 (Figure 4A) 
and E7-APLLA
sc
 (Figure 4B) showed a homogeneous layer 
characterized by a rough surface with lamellar structures 
projecting from the surface (crests). However, the E7-PLLA
sc
 
surface was smoother and more compact than the rough and 
Table 1 advancing and receding contact angles of pristine and 
APLLA films in water measured using a stage speed of 60 µm 
per second
Sample θa (°) θr (°) Δθ = θa - θr (°)
Pristine PLLA film 96.2±0.2 29±5 67±5
APLLA film 85±2 5±3 80±5
Note: The data are reported as the mean ± standard deviation (n=5).
Abbreviations: Plla, poly(l-lactide); aPlla, amino-functionalized poly(l-lactide).
???????????????????
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Figure 3 Protein release experiment.
Notes: e7-Pllasc and e7-aPllasc suspensions were centrifuged and rinsed in 
phosphate-buffered saline five times. The released E7 was quantify in the supernatant 
after each rinse step. The y axis reports the cumulative quantity of E7 released with 
respect to that initially adsorbed on the Plla substrates. The x axis indicates each 
single wash step. The values are the mean of three determinations.
Abbreviations: Plla, poly(l-lactide); e7-Pllasc, e7-containing poly(l-lactide) 
single crystals; e7-aPllasc, e7-containing amino-functionalized poly(l-lactide) single 
crystals.
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nubby E7-APLLA
sc
 sample. Semiquantitative analysis of the 
crests on the surface, performed as described in the Materials 
and methods section, demonstrated that E7-APLLA
sc
 dis-
played 6–7-fold more crests than E7-PLLA
sc
 (Figure 4 and 
data not shown). The size of the crests ranged from about 
5 to 15 µm for E7-APLLA
sc
 and from about 20 to 50 µm 
for E7-PLLA
sc
. These findings suggest a different degree of 
aggregation of the two samples when subjected to the drying 
process. Probably, the formation of a continuous and compact 
layer in PLLA
sc
 was favored by interlamellar surface hydro-
phobic interactions. In contrast, electrostatic repulsion and 
surface hydrophilicity of APLLA
sc
 hampered tight lamella 
aggregation, promoting formation of a rough and porous 
layer with a greater available surface area.
Induction of the E7-specific immune 
response
Preliminary studies were performed to assess the toxicity, 
vaccine dose, and schedule vaccination for PLLA
sc
 and 
APLLA
sc
 in C57BL/6 mice. Acute toxicity tests performed in 
these mice showed that PLLA
sc
 and APLLA
sc
 were not toxic 
to animals at a dose up to 5 mg/g of mouse body weight when 
administered by the subcutaneous or intraperitoneal route. 
In these conditions, neither death nor changes in physiologi-
cal behavior were observed in the treated animals. Moreover, 
we did not detect any anti-PLLA antibodies in mouse serum. 
In addition, neither an anti-E7-specific immune response nor 
tumor protection after HPV16-dependent tumor challenge 
(data not shown) were induced by the polymers. In a previous 
study, it was demonstrated that three 10 µg doses of E7 per 
mouse, composed of protein in particle forms of 45–200 nm 
(free E7), were necessary to induce humoral-mediated and 
cell-mediated immune responses able to protect mice from 
TC-1 tumor challenge.20 To investigate if the PLLA substrates 
had any adjuvant activity able to improve a specific immune 
response of free E7, groups of mice were inoculated three 
times with free E7 adsorbed on either PLLA
sc
 or APLLA
sc
, as 
described in the Materials and methods section. Two weeks 
after the last immunization, the E7-specific antibody and cell-
mediated immune responses were analyzed in a proportion 
of the animals in each immunization group. The remaining 
animals in each group were challenged subcutaneously with 
TC-1 tumor cells to evaluate the protective immune response 
against the engraftment of tumor cells and tumor growth. 
To quantify the humoral immune response and to compare 
the IgG antibody levels obtained in the animals, the sera 
from each group were pooled and the antibody titers were 
determined by endpoint dilution in an E7-based IgG enzyme-
linked immunosorbent assay, after the second and third 
immunization with the E7 particle preparations (Table 2). 
The anti-E7 IgG antibody response increased after the second 
and third doses of E7-APLLA
sc
, free E7, and E7-PLLA
sc
 
whereas no anti-E7 antibody response was detected after 
?????? ??????
??
Figure 4 scanning electron micrographs of e7-Pllasc (A) and e7-aPllasc (B) aggregates.
Notes: a drop of either e7-Pllasc or e7-aPllasc suspension, with the same concentration employed for subcutaneous mouse immunization, was deposited on the sample 
holder. The magnitude scale bars are indicated.
Abbreviations: e7-Pllasc, e7-containing poly(l-lactide) single crystals; e7-aPllasc, e7-containing amino-functionalized poly(l-lactide) single crystals.
Table 2 sera pool titration by endpoint dilution elIsa of 
antibodies against e7 after the second and third doses of vaccine
Antigen Dose 2 Dose 3
e7-aPllasc 1:16,000 1:32,000
e7-Pllasc 1:2,000 1:4,000
e7 1:4,000 1:8,000
aPllasc 1:1 1:1
Pllasc 1:1 1:1
Note: The endpoint titer was an optical density of 0.1.
Abbreviations: Pllasc, poly(l-lactide) single crystals; aPllasc, amino-functionalized 
poly(l-lactide) single crystals.
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immunization with APLLA
sc
 or PLLA
sc
 only (Table 2). 
At the end of the vaccination period, the serum pool from 
mice inoculated with E7-APLLA
sc
 had the highest anti-E7 
IgG titer (1:32,000), whereas the serum pools of mice immu-
nized with free E7 or E7-PLLA
sc
 showed antibody titers of 
1:8,000 and 1:4,000, respectively. These results show that 
only the APLLA
sc
 was able to improve the humoral response 
elicited by E7. Conversely, the presence of pristine PLLA
sc
 
seems to be detrimental for E7 immunogenicity.
The presence of IgM and IgA, driving IgG induction and 
mucosal immunity, respectively, was also analyzed. Signifi-
cant IgM levels were detected only in serum pools from mice 
immunized with APLLA
sc
-E7 or free E7. The IgM levels of 
these two immunization groups were compared by endpoint 
dilution E7-based enzyme-linked immunosorbent assay. 
Notably, the IgM titer in the serum pool from E7-APLLA
sc
-
treated mice (1:1,000) was higher than the IgM titer in the 
serum pool from free E7-treated mice (1:200). The IgA titers 
were undetectable in the serum pools from all the groups 
of mice (data not shown). The titers reported above are the 
mean values of three experiments with sera pools. Overall, 
the results show that the IgG class of immunoglobulins was 
the predominant component of the humoral immune response 
in the three groups of mice.
The effector functions of IgG depend on its subclasses, 
which are also indicative of a Th1 or Th2 polarization of 
the immune response. Therefore, to better evaluate the 
E7-specific humoral immune response, the anti-E7 spe-
cific IgG1, IgG2b, IgG2c (corresponding to IgG2a in the 
C57BL/6 mouse strain), and IgG3 antibody subclasses were 
determined in the serum pools. An enzyme-linked immuno-
sorbent assay result, included in Figure 5, shows that IgG2b 
and IgG2c levels were induced in all mouse groups. The 
anti-E7 IgG1 levels detected were higher in the serum pools 
of mice immunized with either E7-APLLA
sc
 (Figure 5, black 
bar) or E7-PLLA
sc
 (Figure 5, gray bar) compared with the 
sera of mice immunized with free E7 (Figure 5, white bar). 
E7-specific IgG3 values were undetectable in the serum pools 
of all immunization groups. These results show that a mixed 
Th1/Th2 immune response was elicited in all groups of mice 
treated with E7-APLLA
sc
, E7-PLLA
sc
, or free E7. Overall, 
the animals immunized with E7-APLLA
sc
 showed the high-
est induction of E7-specific antibody responses among the 
groups of mice analyzed (IgG, Figure 5, black bar).
To analyze the induction of the cell-mediated immune 
response, T-enriched splenocytes from different immunization 
groups of mice were stimulated in vitro either with two recall 
E7-CTL peptides (pE7) or with an unrelated mixture of peptides 
as a control, and then processed for an IFN-γ ELISPOT assay. 
The results of a representative experiment are shown in 
Figure 6. Significant amounts of IFN-γ-secreting cells were 
detected in T-enriched splenocytes from all three immuniza-
tion groups, ie, E7-APLLA
sc
 (P=0.009), E7-PLLA
sc
 (P=0.01), 
and free E7 (P=0.01). A higher number of E7-specific IFN-
γ-producing cells was detected in the E7-APLLA
sc
 group than 
in the group treated with free E7 (Figure 6). Instead, the lowest 
level of E7-specific IFN-γ-producing cells was detected in the 
E7-PLLA
sc
 group. The results show that all the immunogens 
used were able to induce a significant anti-E7-specific cell-
mediated immune response, although to a different extent. 
Of note, the presence of pristine PLLA
sc
 was detrimental to 
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Figure 5 Determination of immunoglobulin isotypes by enzyme-linked immunos-
orbent assay.
Notes: The E7-specific IgG1, IgG2b, IgG2c and IgG3 immune reactivity is shown 
in OD450 values on the y axis. The bars represent pools from sera of mice groups 
immunized with free e7 (e7, white bars), e7-Pllasc (gray bars), and e7-aPllasc (black 
bars). The four isotypes are indicated on the x axis along with the result of a total Igg 
enzyme-linked immunosorbent assay performed in parallel as control using the same 
serum pools. *Statistically significant result (P,0.05).
Abbreviations: e7-Pllasc, e7-containing poly(l-lactide) single crystals; e7-aPllasc, 
e7-containing amino-functionalized poly(l-lactide) single crystals; Ig, immun oglobulin.
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Figure 6 INF-γ-secreting cells from mice immunized with e7-aPllasc, e7-Pllasc 
and free e7 (e7).
Notes: The cells were stimulated with either an unrelated mixture of peptides (unp, 
black bars) or two cTls e7 peptides (pe7, grey bars). *P=0.009; **P=0.01.
Abbreviations: unp, unrelated mixture of peptides; pe7, e7 peptide; IFN-γ, 
interferon gamma; e7-Pllasc, e7-containing poly(l-lactide) single crystals; e7-
aPllasc, e7-containing amino-functionalized poly(l-lactide) single crystals.
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induction of E7-specific T-cell immune responses, similar to 
what is observed for the antibody response.
To evaluate the efficacy of this anti-E7-specific cell-
mediated immune response in the protection of mice from 
HPV16-dependent tumor development, the mice were 
challenged with TC-1 tumor cells after the immunization 
protocol and tumor growth was monitored for 2 months after 
the challenge.21 The results of a representative experiment 
are shown in Figure 7. Only mice vaccinated with either 
E7-APLLA
sc
 or free E7 were fully protected from tumor 
growth throughout the observation period. In contrast, mice 
immunized with E7-PLLA
sc
, as well as mice in the control 
groups immunized with the APLLA
sc
 or PLLA
sc
 particles 
only and naïve mice developed a palpable tumor (Figure 7) 
within 4 weeks of tumor growth monitoring.
Discussion
During the last decade, several polymer particulate carriers 
have been shown to have intrinsic adjuvant activity when 
added to vaccine formulations to improve the immune 
response.1–3 However, safety concerns restrict the number of 
suitable materials, and further research is required to demon-
strate the absence of risks as well as the real benefits to human 
health.34,35 Biodegradable and biocompatible polyesters are an 
interesting class of substrates because many of them, including 
poly(l-lactide) and its copolymers, have regulatory approval 
for some applications in humans, being degraded in the body 
into endogenous products by non-enzymatic hydrolysis.36,37
In this paper, we compared the properties of pristine 
PLLA
sc
 and APLLA
sc
 and showed that both adsorbed large 
amounts of HPV16-E7 protein. However, when used in 
immunogenicity studies in mice, only APLLA
sc
 demonstrated 
useful features for use in therapeutic vaccine development.
The lamellar PLLA
sc
 surface was amino-functionalized 
to obtain a cationic carrier for HPV16-E7 and possibly to 
increase adsorption by negative E7 charges. However, the 
amount of E7 adsorbed on pristine PLLA
sc
 and APLLA
sc
 
was similar in our conditions. In contrast, the release of E7 
protein in phosphate-buffered saline from APLLA
sc
 and 
PLLA
sc
 was different. The results showed that E7-APLLA
sc
 
released much less E7 protein than E7-PLLA
sc
 in the same 
experimental conditions.
E7 adsorption on PLLA
sc
 and APLLA
sc
 substrates 
could likely be driven by hydrophobic or hydrogen bond/
electrostatic interactions, respectively, which could affect the 
conformation of the adsorbed E7. Even though the E7 pro-
tein used in our experiments was in particulate form,20 SEM 
analyses did not reveal any E7 particles on either APLLA
sc
 
or PLLA
sc
 (data not shown), suggesting that a conforma-
tional change or some degree of aggregation occurred after 
protein–substrate interaction and protein adsorption. The 
poor elution of E7 from the APLLA
sc
 substrate in vitro could 
indeed suggest slow release of the antigen when the complex 
is subcutaneously inoculated as a vaccine in vivo.
The significant quantity of about 300 ng of E7 per mg 
of lamellae was related to the highly specific surface area of 
PLLA
sc
 or APLLA
sc
, and corresponds to about 130 m2/g. Such 
a value was evaluated by geometrical calculations assuming 
a lamella thickness of 12 nm and a PLLA crystalline density 
equal to 1.285 g/cm3.22,31
E7-APLLA
sc
 and E7-PLLA
sc
 aggregation was different 
when the samples were dried for SEM analyses. E7-PLLA
sc
 
formed a compact layer of lamellar (piled-up) aggregates, 
probably due to hydrophobic interlamellae interactions. 
In contrast, the hydrophilic charged surface of APLLA
sc
 
seemed to favor the formation of a rough and nubby layer. 
The different morphology of the dried E7-PLLA
sc
 and 
E7-APLLA
sc
 samples could reflect the real aggregation state 
of the antigen-polymer complexes when they are injected 
subcutaneously into animals. The greater roughness of 
E7-APLLA
sc
, compared with E7-PLLA
sc
, resulted in a greater 
surface area with E7 available to the antigen-presenting cells 
to establish immunity-inducing interactions.
The different behavior of E7-APLLA
sc
 and E7-PLLA
sc
 
complexes observed in vitro could explain the better perfor-
mance of the amino-functionalized substrate in the in vivo 
E7 immunogenicity study. In fact, lower antigen release 
and higher E7 surface availability could be responsible for 
the higher immunogenicity elicited by E7-APLLA
sc
 when 
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Figure 7 Tumor protection experiment.
Notes: Mice naïve or vaccinated with three doses of free e7 (e7), e7-aPllasc, e7-
Pllasc, aPllasc and Pllasc were challenged with 1×105 Tc-1 tumor cells and tumor 
growth was monitored weekly. The x axis indicates weeks of monitoring after tumor 
challenge and the y axis indicates the percentages of animals without tumor.
Abbreviations: e7-Pllasc, e7-containing poly(l-lactide) single crystals; e7-aPllasc, 
e7-containing amino-functionalized poly(l-lactide) single crystals.
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compared with PLLA
sc
 in C57BL/6 mice. It has already been 
shown that the low release of antigens achieved by micropar-
ticles is important for induction of strong and long-lasting 
immunity.37 On the other hand, to maintain high levels of 
circulating antibodies, a small amount of antigen is sufficient 
once the primary immune response has been elicited.37
Despite our interesting results, we cannot exclude the 
existence of other methodologies to adsorb HPV E7 protein 
on PLLA
sc
 surface preserving the E7 immunogenicity.
The analysis of the antibody response of mice immunized 
with E7 adsorbed on either pristine PLLA
sc
 or APLLA
sc
 
showed that the strongest antibody response was obtained by 
immunization with E7-APLLA
sc
, producing both IgGs and 
IgMs. The IgG antibodies were the predominant component 
of this humoral immune response. However, the induction of 
specific IgMs could play an important role by forming immune 
complexes with the antigen and acting like a self-adjuvant.38
In our experiments, E7-specific IgG isotyping showed 
a pattern indicative of a mixed Th1/Th2 immune response. 
A significant cell-mediated immune response was also 
detected by IFN-γ ELISPOT assay in all mice groups ana-
lyzed. Of note, a higher percentage of IFN-γ-producing 
cells was detected in mice immunized with E7-APLLA
sc
 
in comparison with those immunized with E7-PLLA
sc
. The 
difference in T-cell immune response induction was certainly 
the cause of the different immune response to tumor chal-
lenge observed in the immunized mice. In fact, only the 
mice that received E7-APLLA
sc
 were fully protected from 
the tumor challenge, whereas those that received E7-PLLA
sc
 
developed a tumor. It is worthy of note that pristine PLLA
sc
 
reduces the immunogenicity of E7, thus it could represent a 
suitable substrate for the delivery of drugs where any possible 
substrate adjuvant activity should be avoided.
Conclusion
In this study, for the first time, HPV16-E7 was non-covalently 
loaded onto PLLA
sc
 to develop a vaccine against HPV16-
related tumors. The results showed that only aminolysed 
PLLA induced an effective antibody and cell-mediated 
immune response, capable of protecting mice from challenge 
with tumor cells. These findings indicate that E7-APLLA
sc
 
has the potential for use in the development of an HPV16 
therapeutic vaccine.
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